Live feed
Filing
SCHEDULE 13G
SCHEDULE 13G0001172661-26-001355·Aclaris Therapeutics, Inc.
Schedule 13G ownership disclosure
Aclaris Therapeutics Inc
Common Stock, $0.00001 par value · CUSIP: 00461U105
Event date: 2026-03-09
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Deep Track Capital, LP
Shares: 9,345,000.00 · Class: 7.0%
- Deep Track Biotechnology Master Fund, Ltd.
Shares: 9,345,000.00 · Class: 7.0%
- David Kroin
Shares: 9,345,000.00 · Class: 7.0%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001172661-26-001355
- Form type
- SCHEDULE 13G
- Filer
- Aclaris Therapeutics, Inc.
- CIK
- CIK 1557746
- Filed
- Mar 17, 2026
- Reporting period
- Mar 09, 2026
- Description
- Schedule 13G beneficial ownership